Anti-tumor necrosis factor-α therapy and paradoxical autoimmunity in inflammatory bowel disease: a need for risk-aware monitoring Authors: Ji Eun Kim Published: 2026 Tumor necrosis factor-α (TNF-α) inhibitors have transformed the management of inflammatory bowel disease (IBD) and remain important therapeutic options for patients with moderate-to-severe Crohn’s disease and ulcerative colitis [1]. However, accumulating clinical experience suggests that TNF-α blockade may, in a subset of patients, be accompanied by paradoxical immune-mediated disorders rather than only suppressing inflammation [2]. This paradox may reflect the complex role of TNF-α within broader cytokine networks, where inhibition of one inflammatory pathway can alter immune homeostasis and promote alternative immune responses [3]. In this issue of Intestinal Research, Oh et al. [4] provide clinically relevant population-level data on this issue using the Korean National Health Insurance Service database. In this nationwide case-control study, anti-TNF-α exposure in patients with IBD was associated with an increased risk of new-onset autoimmune disease, particularly psoriasis and interstitial lung disease (ILD). Notably, the risk increased relatively early after exposure and then plateaued, suggesting that paradoxical autoimmunity may occur early in susceptible individuals rather than simply accumulating as a late complication of prolonged therapy. These findings are consistent with previous evidence that TNF inhibitors may be associated with immune-mediated inflammatory diseases in patients with IBD [5]. Among these events, psoriasis is the most consistently recognized paradoxical manifestation, with systematic review data showing a meaningful incidence of psoriasis or psoriasiform lesions among IBD patients receiving anti-TNF therapy [6]. A Korean nationwide cohort study also demonstrated an increased risk of psoriasiform disease after TNF antagonist exposure, supporting the relevance of this signal in Korean patients with IBD [7]. Mechanistically, anti-TNF-induced psoriasiform lesions in IBD have been linked to Th1 and Th17 inflammatory pathways, supporting the concept that TNF blockade may redirect rather than simply suppress immune activity [8,9]. The ILD signal reported by Oh et al. [4] is also clinically important, although it should be interpreted cautiously. TNF-targeted therapies have previously been reported to induce or exacerbate ILD, but establishing causality is difficult because infection, underlying immune-mediated disease, and pre-existing lung involvement may confound clinical interpretation [10]. Nevertheless, new respiratory symptoms during anti-TNF-α therapy should prompt careful evaluation rather than being attributed automatically to infection or nonspecific pulmonary complaints. The practical implication is not that anti-TNF-α therapy should be avoided, but that it should be used with risk-aware monitoring [1]. Before initiating treatment, clinicians should consider a focused history of psoriasis, unexplained pulmonary disease, demyelinating disease, lupus-like illness, vasculitis, and other immune-mediated conditions [2]. During treatment, active questioning about new skin eruptions, palmoplantar lesions, cough, dyspnea, and neurologic symptoms may be particularly useful, especially early after anti-TNF-α initiation. The observed association with prolonged concomitant immunosuppressive therapy highlights the need for periodic reassessment of the benefits and risks of combination treatment, although this finding should be interpreted in the context of disease severity and treatment indication. In conclusion, this nationwide study suggests that anti-TNF-α exposure in patients with IBD is associated with an increased risk of new-onset autoimmune disease, especially psoriasis and ILD. Although prospective studies are needed to clarify causality and identify susceptible patients, these findings support careful risk assessment, early symptom-based monitoring, and multidisciplinary evaluation when paradoxical autoimmunity is suspected. Footnotes Funding Source The author received no financial support for the research, authorship, and/or publication of this article. Conflict of Interest Kim JE is an editorial board member of the journal but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported. Data Availability Statement Not applicable. Author Contributions Writing and approval of the final manuscript: Kim JE. REFERENCES